Production and effects of alpha-melanocyte-stimulating hormone during acute lung injury.

Colombo G, Gatti S, Sordi A, Turcatti F, Carlin A, Rossi C, Lonati C, Catania A

Shock (Augusta, Ga.)1 Mar 2007Cited by 23 (Europe PMC)

PMID17304115DOI10.1097/01.shk.0000239764.80033.7ePepBankPUB-17304115

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats with bleomycin-induced acute lung injury, NDP-alpha-MSH treatment was associated with a significant reduction in interstitial edema, with a virtually normal wet/dry weight ratio.
In plain wordsIn rats with lung injury, NDP-alpha-MSH reduced lung swelling, and lung water content looked almost normal.
Peptide
Melanotan I (afamelanotide)
Outcome
DecreaseInterstitial edema and wet/dry weight ratio
Study
ratn: not reported in source
Bleomycin-induced acute lung injury
Comparator
Bleomycin without peptide
Outcome group
Inflammation markers · Respiratory
Studied dose
Dose not stated
Source sentences
Summary
Peptide treatment was associated with a significant reduction in interstitial edema, with a virtually normal wet/dry weight ratio.
2 context sentences(design, population, supporting numbers)
Summary · context
The present research was designed to determine production and effects of alpha-MSH in acute bleomycin-induced lung injury in rats.
Summary · context
In experiments on the therapeutic potential of alpha-MSH on lung injury, we determined influences of the synthetic alpha-MSH analogue [Nle4-dPhe7]-alpha-MSH (NDP-alpha-MSH) on pulmonary edema, circulating nitric oxide, and gene expression profile in lungs 8 and 24 h after bleomycin instillation.
Report a problemFND-1730411501
02AnimalAnimal study (in vivo)Efficacy outcome
In rats with bleomycin-induced lung injury, several stress-related genes that bleomycin had upregulated or reduced were only marginally altered during NDP-alpha-MSH treatment.
In plain wordsIn rats with lung injury, NDP-alpha-MSH left stress-related genes close to normal, although bleomycin had changed them.
Peptide
Melanotan I (afamelanotide)
Outcome
MixedStress-related gene expression
Study
ratn: not reported in source
Bleomycin-induced acute lung injury
Comparator
Bleomycin without peptide
Outcome group
Inflammation markers · Respiratory
Studied dose
Dose not stated
Source sentences
Summary
Several stress-related genes, which were either upregulated or reduced by bleomycin, were only marginally altered during NDP-alpha-MSH treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
The present research was designed to determine production and effects of alpha-MSH in acute bleomycin-induced lung injury in rats.
Summary · context
In experiments on the therapeutic potential of alpha-MSH on lung injury, we determined influences of the synthetic alpha-MSH analogue [Nle4-dPhe7]-alpha-MSH (NDP-alpha-MSH) on pulmonary edema, circulating nitric oxide, and gene expression profile in lungs 8 and 24 h after bleomycin instillation.
Report a problemFND-1730411502
03AnimalAnimal study (in vivo)Efficacy outcome
In rats with bleomycin-induced lung injury, NDP-alpha-MSH prevented bleomycin-related changes in genes of lung fluid homeostasis, including Na/K-transporting ATPase, epithelial sodium channels and CFTR.
In plain wordsIn rats with lung injury, NDP-alpha-MSH stopped bleomycin from changing genes that control lung fluid balance.
Peptide
Melanotan I (afamelanotide)
Outcome
MixedLung fluid homeostasis gene expression
Study
ratn: not reported in source
Bleomycin-induced acute lung injury
Comparator
Bleomycin without peptide
Outcome group
Inflammation markers · Respiratory
Studied dose
Dose not stated
Source sentences
Summary
NDP-alpha-MSH prevented bleomycin-related transcriptional alterations in genes involved in lung fluid homeostasis, including upregulation of Na/K-transporting ATPase and epithelial sodium channels and downregulation of cystic fibrosis transmembrane conductance regulator.
2 context sentences(design, population, supporting numbers)
Summary · context
The present research was designed to determine production and effects of alpha-MSH in acute bleomycin-induced lung injury in rats.
Summary · context
In experiments on the therapeutic potential of alpha-MSH on lung injury, we determined influences of the synthetic alpha-MSH analogue [Nle4-dPhe7]-alpha-MSH (NDP-alpha-MSH) on pulmonary edema, circulating nitric oxide, and gene expression profile in lungs 8 and 24 h after bleomycin instillation.
Report a problemFND-1730411503
04AnimalAnimal study (in vivo)Efficacy outcome
In rats with bleomycin-induced lung injury, NDP-alpha-MSH significantly reduced bleomycin-induced expression of interleukin 6, tumor necrosis factor-alpha, transforming growth factor-beta1 and inducible nitric oxide synthase.
In plain wordsIn rats with lung injury, NDP-alpha-MSH lowered the rise in several inflammation and scarring factors caused by bleomycin.
Peptide
Melanotan I (afamelanotide)
Outcome
DecreaseProinflammatory and profibrotic factor expression (IL-6, TNF-alpha, TGF-beta1, iNOS)
Study
ratn: not reported in source
Bleomycin-induced acute lung injury
Comparator
Bleomycin without peptide
Outcome group
Inflammation markers · Respiratory
Studied dose
Dose not stated
Source sentences
Summary
Bleomycin-induced expression of proinflammatory and profibrotic factors (interleukin 6, tumor necrosis factor-alpha, transforming growth factor-beta1, and inducible nitric oxide synthase)
2 context sentences(design, population, supporting numbers)
Summary · context
The present research was designed to determine production and effects of alpha-MSH in acute bleomycin-induced lung injury in rats.
Summary · context
In experiments on the therapeutic potential of alpha-MSH on lung injury, we determined influences of the synthetic alpha-MSH analogue [Nle4-dPhe7]-alpha-MSH (NDP-alpha-MSH) on pulmonary edema, circulating nitric oxide, and gene expression profile in lungs 8 and 24 h after bleomycin instillation.
Report a problemFND-1730411504
05AnimalAnimal study (in vivo)Efficacy outcome
In rats with bleomycin-induced lung injury, NDP-alpha-MSH significantly reduced bleomycin-induced expression of chemokine CCL2 and CCL5.
In plain wordsIn rats with lung injury, NDP-alpha-MSH lowered the rise in two immune-cell signals caused by bleomycin.
Peptide
Melanotan I (afamelanotide)
Outcome
DecreaseChemokine expression (CCL2, CCL5)
Study
ratn: not reported in source
Bleomycin-induced acute lung injury
Comparator
Bleomycin without peptide
Outcome group
Inflammation markers · Respiratory
Studied dose
Dose not stated
Source sentences
Summary
and chemokines (chemokine [C-C motif] ligand 2 and chemokine [C-C motif] ligand 5) was likewise significantly reduced by NDP-alpha-MSH
2 context sentences(design, population, supporting numbers)
Summary · context
The present research was designed to determine production and effects of alpha-MSH in acute bleomycin-induced lung injury in rats.
Summary · context
In experiments on the therapeutic potential of alpha-MSH on lung injury, we determined influences of the synthetic alpha-MSH analogue [Nle4-dPhe7]-alpha-MSH (NDP-alpha-MSH) on pulmonary edema, circulating nitric oxide, and gene expression profile in lungs 8 and 24 h after bleomycin instillation.
Report a problemFND-1730411505

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.